Creative Medical Technology Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 6, 2025, by Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ), a Nevada corporation. The filing reports the entry into a material definitive agreement involving a warrant exercise inducement.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.7 million from the exercise of existing warrants.
- Existing Warrants Exercised: 837,104 shares at an exercise price of $4.42 per share.
- Inducement Warrants Issued: 1,674,208 new warrants issued to holders.
- Inducement Warrant Terms: Exercise price of $3.75 per share; exercisable for five years following stockholder approval.
- Transaction Costs:
- Financial advisory fee: 8% of gross proceeds.
- Legal expense reimbursement: $40,000.
- Advisor warrants: 5.0% of the aggregate shares issuable upon exercise of both existing and inducement warrants.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Unusual Items
The filing details a significant capital raise event triggered by a warrant exercise inducement. The company agreed to issue new warrants with a lower exercise price ($3.75) compared to the original warrants ($4.42) to incentivize immediate cash exercise. This transaction results in immediate dilution upon the issuance of the inducement warrants and potential future dilution upon their exercise.
Outlook, Risks, and Contingencies
- Stockholder Approval: The Inducement Warrants are not exercisable until the Company obtains stockholder approval for the issuance of the underlying shares, as required by Nasdaq rules.
- Registration: The Company has agreed to file a resale registration statement on Form S-3 within thirty days of closing to register the resale of shares underlying the Inducement Warrants.
- Unregistered Securities: The Inducement Warrants were issued in a private placement under Section 4(a)(2) of the Securities Act and have not been registered.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% advisory fee and $40,000 legal reimbursement.
- Confirm the timeline for the required stockholder vote to enable exercise of the Inducement Warrants.
- Review the full text of the Inducement Letters (Exhibit 10.1) and Inducement Warrants (Exhibit 4.1) for specific vesting or forfeiture conditions.
- Monitor the filing of the Form S-3 resale registration statement within the 30-day window.